Abstract
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.
MeSH terms
-
Age Factors
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Child
-
Drug Resistance, Neoplasm
-
Evidence-Based Medicine / standards
-
Hematopoietic Stem Cell Transplantation / methods*
-
Humans
-
Infant
-
Medical Oncology / methods
-
Medical Oncology / standards*
-
Molecular Targeted Therapy / standards
-
Neoplasm Recurrence, Local / diagnosis
-
Neoplasm Recurrence, Local / mortality
-
Neoplasm Recurrence, Local / therapy*
-
Organizations, Nonprofit / standards
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
-
SEER Program / statistics & numerical data
-
Survival Rate / trends
-
Transplantation, Homologous
-
Treatment Outcome
-
United States / epidemiology